455 related articles for article (PubMed ID: 18409194)
1. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.
Lescot E; Bureau R; Rault S
Peptides; 2008 May; 29(5):680-90. PubMed ID: 18022732
[TBL] [Abstract][Full Text] [Related]
3. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Lavecchia A; Cosconati S; Novellino E
J Med Chem; 2005 Apr; 48(7):2480-92. PubMed ID: 15801838
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies on the human neuropeptide S receptor and its antagonists.
Dal Ben D; Antonini I; Buccioni M; Lambertucci C; Marucci G; Vittori S; Volpini R; Cristalli G
ChemMedChem; 2010 Mar; 5(3):371-83. PubMed ID: 20087922
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
6. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.
Boivin S; Ségalas-Milazzo I; Guilhaudis L; Oulyadi H; Fournier A; Davoust D
Peptides; 2008 May; 29(5):700-10. PubMed ID: 18423797
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the active conformation of urotensin II.
Carotenuto A; Grieco P; Campiglia P; Novellino E; Rovero P
J Med Chem; 2004 Mar; 47(7):1652-61. PubMed ID: 15027856
[TBL] [Abstract][Full Text] [Related]
9. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
Holleran BJ; Beaulieu ME; Proulx CD; Lavigne P; Escher E; Leduc R
Biochem J; 2007 Feb; 402(1):51-61. PubMed ID: 17064254
[TBL] [Abstract][Full Text] [Related]
10. Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP.
Lescot E; Sopkova-de Oliveira Santos J; Dubessy C; Oulyadi H; Lesnard A; Vaudry H; Bureau R; Rault S
J Chem Inf Model; 2007; 47(2):602-12. PubMed ID: 17381176
[TBL] [Abstract][Full Text] [Related]
11. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.
Disa J; Floyd LE; Edwards RM; Douglas SA; Aiyar NV
Peptides; 2006 Jun; 27(6):1532-7. PubMed ID: 16290260
[TBL] [Abstract][Full Text] [Related]
13. Urotensin-II receptor peptide agonists.
Carotenuto A; Grieco P; Novellino E; Rovero P
Med Res Rev; 2004 Sep; 24(5):577-88. PubMed ID: 15224381
[TBL] [Abstract][Full Text] [Related]
14. Identification of new agonists of urotensin-II from a cyclic peptide library.
Odagami T; Tsuda Y; Kogami Y; Kouji H; Okada Y
Bioorg Med Chem; 2009 Sep; 17(18):6742-7. PubMed ID: 19695883
[TBL] [Abstract][Full Text] [Related]
15. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
[TBL] [Abstract][Full Text] [Related]
16. Urantide conformation and interaction with the urotensin-II receptor.
Brancaccio D; Limatola A; Campiglia P; Gomez-Monterrey I; Novellino E; Grieco P; Carotenuto A
Arch Pharm (Weinheim); 2014 Mar; 347(3):185-92. PubMed ID: 24357333
[TBL] [Abstract][Full Text] [Related]
17. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
19. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor.
Foister S; Taylor LL; Feng JJ; Chen WL; Lin A; Cheng FC; Smith AB; Hirschmann R
Org Lett; 2006 Apr; 8(9):1799-802. PubMed ID: 16623554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
